drugset / Trial / NCT00157534

A Study to Evaluate the Safety and Efficacy of Celgosivir in Patients With Chronic Hepatitis C Genotype 1 Infection

NCT00157534

Phase 2 Completed 43 enrolled BioWest Therapeutics Inc
RandomizedParallel-groupOpen-labelTreatment

Summary

The objective of the study is to evaluate the safety and efficacy of celgosivir for 12 weeks in patients with chronic hepatitis C genotype 1 infection.

Timeline

Start
2004-10
Primary completion
Completion
2005-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Celgosivir Small molecule